• Home
  • News
    • Politics & Government
    • Business & Economy
    • Crime / Courts
    • Health / Medicine
  • Sports
    • High School Sports
    • Radio Iowa Poll
  • Affiliates
    • Affiliate Support Page
  • Contact Us
    • Reporters

Radio Iowa

Iowa's Radio News Network

You are here: Home / Business / Drug company settles over marketing concerns for Arasnep and Enbrel

Drug company settles over marketing concerns for Arasnep and Enbrel

August 20, 2015 By Dar Danielson

PillsThe drug company Amgen Incorporated is paying the State of Iowa $972,000 in a settlement over the way it marketed two of its medications. Iowa Attorney General spokesman, Geoff Greenwood, says one of the issue was in the marketing of Aranesp.

“What we allege with Aranesp is that Amgen promoted it for things that the FDA didn’t approve,” Greenwood says. “Things like using it for longer periods than the FDA approved and using it for cancer treatment — anemia associated with cancer — when the FDA said you can’t do it for that.” Greenwood says the FDA sets the guidelines for the drugs and promoting “off label” or unapproved uses is unlawful.

He says the same thing was happening with Enbrel. “With Enbrel…we allege Amgen promoted its use for mild plaque psoriasis, when the FDA only approved it for severe plaque psoriasis. So, we alleged that the company was marketing these drugs, was selling these drugs for uses the FDA did not approve,” Greenwood says. Greenwood says the company was profiting by misleading people.

“We don’t think Iowans should have to worry about whether they are getting the straight story about a prescription drug. Whether they’re taking the drug for the right condition, or whether the drug could put them at risk for something the FDA didn’t approve,” Greenwood says.

Iowa is part of the agreement with 48 states and the District of Columbia. “We think this settlement holds Amgen accountable for deceptive marketing here in Iowa and it sends a message that we are going to take action against any drug company that puts sales ahead of safety. And when it comes to people’s health that’s really important,” Greenwood says, “drug companies should be promoting their own drugs for approved uses only and not for off-label uses.”

Iowa’s $972,000 from the 72 million dollar agreement will go to the state’s consumer education and litigation fund.

 

Share this:

  • Facebook
  • Twitter

Filed Under: Business, Crime / Courts, News

Featured Stories

Exhibit features lesser known works of Grant Wood

Testing finds 21 new CWD cases in deer

It may become a crime in Iowa to use fake urine in workplace drug tests

February trending 18 degrees below average temperature

Iowa House Education Committee votes to end tenure at UI, ISU, UNI

TwitterFacebook
Tweets by RadioIowa

Confusion at MVC Tournament as UNI exits prior to quarterfinal round game

Iowa State looks to avoid winless Big-12 season

New look and new format at girls’ state basketball

Youngstown State takes action against assistant football coach

Iowa’s Jack Nunge lost for the season

More Sports

eNews and Updates

Enter your email address:

Delivered by FeedBurner

Archives

Copyright © 2021 · Learfield News & Ag, LLC